Scientists have announced a significant breakthrough in the development of a drug to combat Alzheimer's disease. The drug, ...

Further research could also help explain and even predict variation in the onset of behavioral changes in people with ...

The drug is RI-AG03, and it's a peptide inhibitor (a blocker of proteins). In tests on fruit flies and human cells, it has ...

A peptide inhibitor called RI-AG03 targets major aggregation “hot spots” of tau proteins, believed to be a key driver of ...

In two papers, published in Cell and Science, they demonstrate how utilizing the unique capabilities of a protein called TRIM21 gives the potential therapies two key advantages. Firstly, they only ...

“This research is taking promising steps towards a new one-of-a-kind therapy which targets tau, a damaging protein in the ...

Researchers have discovered that disruptions in the brain’s salience network, often tied to tau protein buildup, correlate strongly with behavioral changes in people with early-stage dementia.

AG03, developed by researchers at the University of Southampton, targets two critical regions of the tau protein linked to ...

AG03, targets two key areas of the Tau protein in Alzheimer's disease, showing effectiveness in lab and fruit fly models.

An international team of researchers has made a significant breakthrough in Alzheimer's drug development with the ...

DEPTAC. Based on PROTACs, or protein-targeting chimeras, D20, a dephosphorylation-targeting chimera, delivers PP1 to tau. The C-terminal tail (gray) helps the construct enter cells. [Courtesy of Xiao ...